Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) is anticipated to release its earnings data before the market opens on Tuesday, March 25th. Analysts expect Acumen Pharmaceuticals to post earnings of ($0.47) per share for the quarter. Individual interested in registering for the company's earnings conference call can do so using this link.
Acumen Pharmaceuticals Stock Performance
Shares of ABOS stock traded up $0.03 during trading on Friday, hitting $1.21. The company's stock had a trading volume of 178,276 shares, compared to its average volume of 293,169. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.14. The company has a market cap of $72.40 million, a PE ratio of -0.88 and a beta of 0.02. The business has a fifty day moving average of $1.43 and a 200-day moving average of $2.04. Acumen Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $4.43.
Insider Transactions at Acumen Pharmaceuticals
In other news, CFO Matt Zuga sold 28,902 shares of the company's stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $1.72, for a total transaction of $49,711.44. Following the transaction, the chief financial officer now owns 231,744 shares of the company's stock, valued at $398,599.68. This represents a 11.09 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel Joseph Oconnell sold 47,778 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $1.84, for a total value of $87,911.52. Following the transaction, the chief executive officer now owns 454,707 shares of the company's stock, valued at $836,660.88. The trade was a 9.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 131,526 shares of company stock worth $233,124 in the last ninety days. Company insiders own 7.10% of the company's stock.
About Acumen Pharmaceuticals
(
Get Free Report)
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.
Further Reading
Before you consider Acumen Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acumen Pharmaceuticals wasn't on the list.
While Acumen Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
